Browsing by Author "Beypinar, Ismail"

Now showing 1 - 4 of 4

Covıd-19 Pandemı̇sı̇nı̇n Palyatı̇f Bakım Merkezı̇ndekı̇ Kanser Hastaları Üzerı̇ndekı̇ Etkı̇sı̇nı̇n Değerlendı̇rı̇lmesı̇; Öncesi & Sonrası
(2024) Kaya, Zeynep İrmak; Beypinar, Ismail; Urun, Muslih
AMAÇ: Kanser hastalarında COVID-19 enfeksiyonundan kaynaklanan yüksek ölüm riskine ek olarak, kanser tanısındaki gecikmeler kanser hastalarının tedavisinin gecikmesine neden olabilir. Bu çalışmada, Türkiye'de pandemi öncesi ve sonrası bir yıllık dönemler arasında kanser hastalarının tanı, evre ve prognoz gibi özelliklerindeki değişikliklerin değerlendirilmesi amaçlanmıştır. GEREÇ VE YÖNTEM: Palyatif serviste 11 Mart 2019 ile 11 Mart 2021 tarihleri arasında palyatif tedavi alan hastaların kayıtları retrospektif olarak incelendi. Hasta dosyalarından yaş, cinsiyet, tanı, tanı tipi, tedavi tipi, palyatif servise geliş yeri ve taburculuk şekli retrospektif olarak tarandı. Tekrarlayan yatışları olan hastaların ilk yatışları değerlendirildi. Hasta kayıtları yetersiz olan hastalar çalışma dışı bırakıldı. BULGULAR: Radyolojik olarak kanser tanısı konulan hastaların oranı artmıştır. Pandemi öncesi dönemde hastaların %9,1'inde radyolojik olarak kanser bulgusu saptanırken, pandemi sonrası dönemde bu oran %16,2 idi. Hastalar yatarak palyatif bakım öncesi aldıkları onkolojik tedavi açısından değerlendirildiğinde anlamlı fark saptandı (p=0,002). Bu fark pandemi sonrası onkolojik tedaviye uygun olmayan hastaların oranındaki artıştan kaynaklanmaktaydı. SONUÇ: Pandeminin yeni tanı alan ve palyatif bakım hizmetlerine ihtiyaç duyan hastalar üzerinde büyük etkileri olduğunu düşünüyoruz. Bu çalışmada, pandemi sonrası dönemde radyolojik olarak kanser tanısı alan ve palyatif bakım servislerinde tedavi gören kanser hastalarında artış gözlemlendi.
Inflammatory Biomarkers From Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer
(int Scientific information, inc, 2025) Urun, Yonca Yilmaz; Beypinar, Ismail
Background: Globally, esophageal cancer ranks as the sixth leading cause of cancer-related mortality. This retrospective study from a single center in Turkey aimed to evaluate hematological inflammatory biomarkers in complete blood count (CBC) data and outcomes in 113 patients with advanced esophageal carcinomas. Material/Methods: We conducted a retrospective analysis of 113 patients with metastatic esophageal cancer composed of squamous (92), adenocarcinoma (18), and small cell (3) histology. We investigated neutrophil-to-lymphocyte ratio tory response index (SIRI), and aggregate index of systemic inflammation (AISI) in terms of prognosis. Results: The initial treatment for 25.7% of patients consisted of a carboplatin-paclitaxel combination. In response to the initial round of chemotherapy, 52.2% of patients showed improvement (15% complete, 37.2% partial), while 18.6% experienced disease progression. Neutropenia was observed as the most prevalent severe (grades 3-4) adverse reaction, affecting 19.8% of patients. Higher NLR, PLR, SII, NLPR, SIRI, and AISI values were associated with worse survival (P=0.016, P=0.008, P=0.011, P=0.028, P=0.014, P=0.001, respectively), whereas higher LMR was correlated with better survival (P=0.001). The NMR analysis showed no significant association (P=0.46). Multivariate analysis identified independent prognostic factors except histology, PLR, and NLPR. Conclusions: Research indicates that inflammatory indicators obtained from complete blood count analyses possess prognostic significance for individuals with metastatic esophageal cancer. These biomarkers demonstrate diverse capacities in forecasting the course of the disease. These simple and inexpensive markers need further confirmation to guide individualized treatment planning.
Prognostic Value of Imdc Score in Non-Small Cell Lung Cancer Receiving Immunotherapy: Old Dog, New Tricks
(Springer Heidelberg, 2025) Beypinar, Ismail; Urvay, Semiha; Urun, Muslih; Ercek, Berrak; Demir, Hacer; Yildiz, Canan; Balcik, Onur Yazdan
Background Although there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical parameters of IMDC risk groups at the time of diagnosis to predict the effectiveness of immunotherapy. Methods This multicenter cross-sectional study retrospectively analyzed non-small cell lung cancer (NSCLC) patients receiving nivolumab for the prognostic effects of clinical factors, including the IMDC score. Results Two hundred and five patients were enrolled in this study. There was no favorable group because the TTI was less than 1 year in the entire study group in the IMDC. The IMDC score and IMDC groups showed significant differences in PFS (p < 0.001; p < 0.001, respectively). Intermediate and poor-risk groups had PFS of 8 and 3 months PFS, respectively. The IMDC group showed a significant effect on OS (p = 0.002). The intermediate- and poor-risk groups had 12- and 4-month OS, respectively. The TTI risk factor excluded patient numbers in the favorable, intermediate, and poor risk groups were 47, 129, and 29, respectively, in the revised IMDC group (rIMDC). The prognostic effect of the rIMDC score and groups remained significant (p < 0.001 and p < 0.001, respectively). The classical IMDC had a significant effect on PFS in the multivariate analysis (p = 0.016). Also, rIMDC score in multivariate analysis resulted with significant effect on OS (p = 0.035). Conclusion To date, this is the first study to prove that the IMDC may be a valuable option for predicting both prognosis and treatment efficacy in NSCLC patients receiving especially second or further lines nivolumab treatment.
The Real-Life Data of Braf Mutation on the Treatment of Colorectal Cancer: a Tog Study
(Springer, 2021) Beypinar, Ismail; Demir, Hacer; Sakin, Abdullah; Taskoylu, Burcu Yapar; Sakalar, Teoman; Ergun, Yakup; Artac, Mehmet
Purpose Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide. The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists. The median overall survival (OS) of these types of cancers is reported to be 9 to 14 months. Methods The study was declared on the Turkish Oncology Study Group Conference and approved. The patients' data was received from the centers who confirmed to participate. The BRAF-mutated patients were included in the study. The demographic features (age, gender, etc.), type of mutation, tumor localizations, histology, microsatellite instability (MSI) status, metastasis patterns chemotherapeutic agents and progression, and death times were recorded. Results Thirty-nine patients were enrolled in the study. Sixteen patients had concurrent KRAS mutations, while 7 had NRAS mutations. Most of the patients received doublet chemotherapies in combination with anti-VEGF agents in the first and second line of the treatment. There was a significant difference in OS according to the stage which showed a decreased survival in stage IV patients at the time of diagnosis. Concurrent KRAS mutation resulted in increased OS. The median OS was 47 and 24 months favoring the KRAS mutant group. The patients whose primary tumor operated had better survival when compared with other patients. The median OS of the operated group was 47 months, while the non-operated group was 24 months. Liver metastasis was related to worse prognosis at the time of diagnosis in univariate analysis. Conclusion In our study we found a high concurrent RAS mutation ratio in a BRAF mutant patient group which was different from prior studies. The concurrent mutations resulted in a favorable outcome in terms of OS which is also different from the current knowledge. More prospective studies are needed especially BRAF-mutated patient population and especially with concurrent RAS mutations.